Ibogaine shares receptor effects with both Salvia divinorum (κ-opiate down-regulation of tolerance via beta-arrestin) and with ketamine (NMDA antagonism, curbing narcotic withdrawal and super-sensitization to stimulants). Additionally, ibogaine induces the nerve growth factor GDNF (Glia-Derived Neurotrophic Factor), re-sprouting chronically desensitised dopamine receptors and replacing the neural deficit experienced as craving. Moreover, the 10-fold GDNF spike engendered by ibogaine back-signals to cell nuclei to make more GDNF, setting up a benign auto-regulatory loop accounting for ibogaine’s persistent effect. This is supported by recent cases in which as little as 4 mgs of ibogaine twice a day for 28 days significantly reversed Parkinson’s degeneration. Alper proposed that ibogaine is a true oneiric, experienced as “a dream body in a dream landscape.” This was elaborated in Carl Anderson’s prescient MAPS paper on ibogaine and fetal REM. Not only may fetal REM orchestrate neonatal growth, ibogaine REM-mimesis may be “resetting” adult immune systems – as seen in amelioration of auto-immune disorders such as MS and Crohn’s disease, and some complications of AIDS.
Filmed at Breaking Convention 2017
4th International Conference on Psychedelic Consciousness
University of Greenwich London – June 30th – July 2nd 2017